体内免疫疗法研发商CREATE Medicines宣布完成1.22亿美元B轮融资，以推进自身免疫疾病和肿瘤学领域的体内CAR管线发展-动脉网

CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology

CISION 等信源发布 2026-05-14 19:58



可切换为仅中文







Financing to support advancement of CREATE's repeat dose capable CD19 targeted in vivo CAR-T therapy for autoimmune disease into the clinic, expansion of its dual CAR CD19 x BCMA program, and continued progress across the oncology portfolio

为支持CREATE公司推进其针对自身免疫性疾病的可重复剂量CD19靶向体内CAR-T疗法进入临床、扩展其双重CAR CD19 x BCMA项目以及继续在肿瘤学组合中取得进展提供资金支持。

Round co-led by existing investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, reflecting conviction in CREATE's clinical trajectory and platform

由现有投资者Newpath Partners、ARCH Venture Partners和Hatteras Venture Partners共同领投，体现了对CREATE临床发展轨迹和平台的信心。

Ron Philip joins as Executive

Ron Philip 加入担任行政职务

Chairman

董事长

;

；

Brian Cuneo

布赖恩·库内奥

的

ARCH Venture Partners and Tom Thomas, PhD,

ARCH风险合伙人和汤姆·托马斯博士，

的

Newpath Partners

新路径合作伙伴

join t

加入 t

he Board of Directors

董事会

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

May 14, 2026

2026年5月14日

/PRNewswire/ -- CREATE Medicines, Inc. ('CREATE'), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the closing of its $122 million Series B funding round, co-led by existing investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other current members of CREATE's investor syndicate..

/PRNewswire/ -- CREATE Medicines, Inc.（简称“CREATE”），一家处于临床阶段的生物技术公司，专注于在体内免疫编程领域的创新，今天宣布完成了1.22亿美元的B轮融资。本轮融资由现有投资者Newpath Partners、ARCH Venture Partners和Hatteras Venture Partners共同领投，Alexandria Venture Investments及其他CREATE投资者财团的现有成员也参与其中。

The funding will support advancement of CREATE's clinical pipeline across autoimmune disease and oncology. To date, CREATE has dosed more than 50 patients across its in vivo CAR clinical programs — the largest clinical dataset in the field — generating the translational foundation that informs development across both autoimmune disease and oncology.

这笔资金将支持CREATE在自身免疫疾病和肿瘤学领域的临床管线进展。迄今为止，CREATE已经在其体内CAR临床项目中为50多名患者进行了给药，这是该领域最大的临床数据集，为自身免疫疾病和肿瘤学领域的发展提供了转化基础。

The company's proprietary mRNA-LNP platform programs immune cells directly inside the body, enabling a rapid, iterative product engine designed to compress concept-to-clinic timelines..

公司的专有 mRNA-LNP 平台直接在体内编程免疫细胞，实现快速、迭代的产品引擎，旨在压缩从概念到临床的时间线。

In autoimmune, CREATE's lead program CRT-402, a next generation CD19 targeted in vivo CAR-T therapy, has demonstrated deep and durable B cell depletion in non-human primates, with the potential to enable immune reset through the flexibility of repeat dosing. The company is also advancing a dual CAR CD19 x BCMA directed therapy designed to broaden therapeutic reach across refractory autoimmune indications..

在自身免疫疾病领域，CREATE公司的主导项目CRT-402是一种下一代靶向CD19的体内CAR-T疗法，已在非人灵长类动物中显示出深度且持久的B细胞清除效果，并通过灵活的重复给药策略有望实现免疫重置。该公司还正在推进一种双CAR CD19 x BCMA导向疗法，旨在拓宽对难治性自身免疫适应症的治疗覆盖范围。

In oncology, CREATE continues to advance therapies focused on areas of high unmet need. Early clinical data from the company's MT-303 program in frontline hepatocellular carcinoma has demonstrated an extremely compelling response profile.

在肿瘤学领域，CREATE继续推进针对高度未满足需求领域的疗法。公司MT-303项目在一线肝细胞癌的早期临床数据展现了一个非常引人注目的响应情况。

Collectively, these programs exemplify CREATE's iterative platform that integrates clinically validated CAR architectures, optimized RNA design, and targeted delivery technologies with deep expertise across clinical development, translational medicine, manufacturing, and regulatory execution.

这些项目共同体现了CREATE的迭代平台，该平台整合了经过临床验证的CAR架构、优化的RNA设计和靶向递送技术，并在临床开发、转化医学、制造和监管执行方面拥有深厚的专业知识。

'CREATE was built as an iterative immune programming platform in which each clinical study informs and strengthens the next, and it is that work that has revealed the breadth of what in vivo immune programming can address,' said Daniel Getts, PhD, Chief Executive Officer of CREATE Medicines. 'Our autoimmune and oncology pipeline represents the convergence of years of platform development, clinical execution, and translational learning.

“CREATE是一个迭代的免疫编程平台，每一项临床研究都为下一项研究提供信息并增强其效果，正是这项工作揭示了体内免疫编程所能解决的广泛问题，”CREATE Medicines首席执行官Daniel Getts博士表示。“我们的自身免疫和肿瘤学管线代表了多年平台开发、临床执行和转化学习的成果。”

We believe our ability to engineer multiple immune cell populations directly in vivo has the potential to fundamentally reshape treatment paradigms across autoimmune disease and oncology, and we look forward to this next chapter of innovation and growth.'.

我们相信，我们直接在体内工程化多个免疫细胞群体的能力有潜力从根本上重塑自身免疫疾病和肿瘤学的治疗范式，我们期待着这一创新与增长的新篇章。

In conjunction with the Series B Round, Ron Philip, a veteran biopharma leader, has joined CREATE as Executive Chairman. Brian Cuneo, Senior Partner at ARCH Venture Partners, and Tom Thomas, PhD of Newpath Partners, have joined the company's Board of Directors.

在B轮融资的同时，资深生物医药行业领袖罗恩·菲利普 (Ron Philip) 加入CREATE担任执行主席。ARCH Venture Partners的高级合伙人布莱恩·库内奥 (Brian Cuneo) 以及Newpath Partners的汤姆·托马斯 (Tom Thomas) 博士加入了公司董事会。

'I'm excited to join CREATE at this pivotal moment in the company's evolution,' said Ron Philip. 'CREATE has established meaningful in vivo clinical proof points and built a differentiated immune programming platform with the potential to redefine how engineered immune therapies are developed and delivered.

“我非常高兴在这个公司发展的关键时刻加入CREATE，”Ron Philip表示。“CREATE已经建立了有意义的体内临床验证点，并构建了一个差异化的免疫编程平台，有潜力重新定义工程化免疫疗法的开发和交付方式。”

The opportunity to translate these capabilities into transformative medicines across autoimmune disease and oncology is exceptionally compelling.'.

将这些能力转化为自身免疫疾病和肿瘤学领域的变革性药物的机会非常令人信服。

'I co-founded this company because the science was ahead of the field. More than fifty patients later, it still is. Most in vivo cell therapy companies will struggle to translate science into scalable manufacturing. CREATE owns its manufacturing infrastructure. I am backing CREATE because it can become the next great standalone pharmaceutical company,' said Tom Cahill, MD, PhD, Founder and Managing Partner of Newpath Partners..

“我共同创立了这家公司，因为它的科学水平超前于整个领域。在治疗了五十多名患者后，它依然保持领先。大多数体内细胞治疗公司都会在将科学转化为可扩展的生产过程中遇到困难。而CREATE拥有自己的制造基础设施。我支持CREATE，因为它有可能成为下一个伟大的独立制药公司。” Newpath Partners的创始人兼管理合伙人Tom Cahill医学博士说道。

'CREATE is building one of the most differentiated in vivo immune engineering platforms in the field,' said Brian Cuneo. 'We believe the company's clinical experience, repeat dose strategy, and broad immune programming capabilities position it to play an important role in the future of autoimmune disease and oncology.'.

“CREATE 正在构建领域内最具差异化的体内免疫工程平台之一，”Brian Cuneo 表示。“我们认为，该公司的临床经验、重复给药策略以及广泛的免疫编程能力，使其在未来自身免疫疾病和肿瘤学领域中扮演重要角色。”

About CREATE Medicines

关于CREATE药品

CREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly engineers T cells, NK cells, and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies. CREATE is advancing a pipeline of in vivo CAR therapies across autoimmune diseases and cancer..

CREATE医药公司是一家临床阶段的生物技术公司，致力于在体内免疫编程领域的创新。该公司专有的mRNA-LNP平台能够直接在体内改造T细胞、NK细胞和髓系细胞，从而实现可扩展、可重复给药、即用型的免疫疗法。CREATE正在推进一系列针对自身免疫疾病和癌症的体内CAR疗法的研发管线。

For more, visit

欲了解更多信息，请访问

createmedicines.com

创药网

. Follow us on

. 关注我们

领英

and

和

(Twitter).

（推特）。